Neonatal Intensive Care UnitChildren's Hospital


Disclaimer to the On-line Edition
This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.



  • the active immunization of children from 2 months of age for the prevention of invasive disease caused by Neisseria meningitidis serogroup C


  • Menjugate ® will NOT protect against meningococcal diseases caused by any of the other types of meningococcal bacteria
  • complete protection against meningococcal serogroup C infection cannot be guaranteed

Side Effects

  • the most common postimmunization reactions shown in clinical trials were local tenderness (31%), irritability (81%), sleepiness (69%), change in eating (46%), diarrhea (43%), vomiting (34%) and high-pitched crying (38%)


  • 0.5mL, deep IM (anterolateral thigh)
  • a total of 3 doses, the first not earlier than 2 months of age, with an interval of at least 1 month between doses


  • the lyophilized vaccine requires reconstitution with the liquid diluent by following these steps:
    • gently agitate the liquid diluent vial
    • withdraw 0.6mL of the diluent and use it to reconstitute the lyophilized Menjugate® vaccine
    • gently shake the reconstituted vial until the vaccine is dissolved
    • following reconstitution the vaccine is a slightly opaque homogeneous suspension
    • menjugate® should NOT be mixed with other vaccines in the same syringe; however, it may be administered at the same time (as a separate injection) as DPTP and HIB vaccines


  • Menjugate® is supplied as a single dose (0.5mL), consisting of 1 vial of vaccine and 1 vial of diluent
  • Menjugate® vaccine will be available for any baby (from London-Middlesex) born up until the end of August 2001
  • refrigerate; do NOT freeze; protect from light


  1. Menjugate® (Meningococcal Group C - CRM 197 Conjugate Vaccine) Product Monograph, Merck Frosst, 24 April 2001.

Date of Preparation: 26 July 2001

Last Uploaded: Thursday, 26-May-2011 00:53:44 EDT